(RTTNews) - AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the conditional marketing authorization of epcoritamab, the first T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies. The European Commission decision on this indication is anticipated later in the current year.
Epcoritamab is being co-developed by AbbVie and Genmab. They will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
